Difference between revisions of "Anti-Fibrinolytic"
Jump to navigation
Jump to search
Mfrdmanager (talk | contribs) |
Mfrdmanager (talk | contribs) |
||
| Line 19: | Line 19: | ||
* History of Seizures | * History of Seizures | ||
* Ischemic event: Myocardial Infarction, stroke, pulmonary embolism (PE), deep venous thrombosis (DVT) | * Ischemic event: Myocardial Infarction, stroke, pulmonary embolism (PE), deep venous thrombosis (DVT) | ||
| − | + | ||
'''PRECAUTIONS''' | '''PRECAUTIONS''' | ||
Revision as of 05:17, 19 November 2019
Section 8 - MEDICATION GUIDELINES
8.20 ANTI-FIBRINOLYTICS
Tranexamic Acid (TXA)
DESCRIPTION
- Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding.
INDICATIONS
- Severe Hemorrhagic Shock.
- Strongly consider in non-traumatic bleeding (post-partum, gastrointestinal, postoperative, nasal)
PREGNANCY CATEGORY
- B - Safe in Pregnancy
- Safe in breastfeeding
CONTRAINDICATIONS
- Hypersensitivity to TXA
- Colorblindness
- History of Seizures
- Ischemic event: Myocardial Infarction, stroke, pulmonary embolism (PE), deep venous thrombosis (DVT)
PRECAUTIONS
- Rapid injection can cause hypotension
DOSAGE
- 1000 mg of TXA mixed in 100 ml or 250 ml of normal saline infused via IO or IV over 10 minutes.
- 20mg/kg (1000mg maximum) TXA mixed in 100 ml of Normal Saline infused via IO or IV over 10 minutes.
